What is the Osteoporosis Self Assessment Tool?
The Osteoporosis Self Assessment Tool (OST) is a brief, two-variable index based on chronological age and current body weight (expressed in kilograms). It was developed to support decisions about when to move from general osteoporosis awareness to formal bone mineral density (BMD) measurement, most often with dual-energy X-ray absorptiometry (DXA). Unlike multicomponent risk questionnaires, OST deliberately keeps inputs minimal so it can be applied quickly in busy primary care, community screening, or self-assessment contexts—provided weight is measured accurately and the result is interpreted alongside clinical judgment and current guidelines.
Why a tool that uses only weight and age?
Osteoporosis and low BMD are common, under-diagnosed, and associated with fragility fractures that carry major morbidity and health-system cost. Yet not every adult requires immediate DXA, and resource constraints often make universal densitometry impractical. Screening strategies therefore aim to identify people at higher pre-test probability of low BMD who are most likely to benefit from testing and treatment discussions.
Low body weight relative to age is a well-recognized marker of lower bone mass in population studies; advancing age is a dominant determinant of fracture risk. OST combines these two signals into a single continuous score with simple arithmetic. The intent is not to diagnose osteoporosis from the score alone, but to stratify who should be offered or prioritized for BMD testing within systems that adopted the published thresholds.
The OST formula
OST is calculated as:
OST = 0.2 × (weight in kg − age in years)Because multiplying by 0.2 is the same as dividing by five, an equivalent form is:
OST = (weight in kg − age in years) ÷ 5Weight must be true measured body weight in kilograms, not ideal weight, recalled weight from years past, or clothing-estimated weight. Small errors in weight materially change the index, especially in borderline cases near the screening cutoffs. Age should reflect the person’s current age in whole years as used in the original instrument descriptions and nomograms.
The score is unbounded in theory: when weight is low relative to age, OST trends lower; when weight is higher relative to age, OST trends higher. That behavior matches the clinical intuition that frail, low-weight older adults are more likely to harbor low BMD, while heavier younger adults are less often flagged by this particular rule—though exceptions always exist at the individual level.
Sex-specific cutoffs and how they are used
Published applications of OST emphasize different numeric thresholds for women and men when using the score as a triage gate for BMD testing:
| Sex | Common published cutoff | Typical interpretation in screening pathways |
|---|---|---|
| Female | OST ≤ 2 | Often treated as the range in which bone densitometry is more strongly considered because validation work suggested high sensitivity for identifying individuals with low BMD, at the cost of more false positives. |
| Male | OST ≤ 1 | A lower numeric threshold reflects male-specific validation and the different baseline risk architecture; the same conceptual role applies—prioritization of testing rather than a stand-alone diagnosis. |
Scores above these cutoffs are often associated with a lower modeled probability of low BMD in derivation cohorts. That does not mean DXA is “never indicated”: major risk factors (prior low-trauma fracture, prolonged glucocorticoids, certain endocrine disorders, parental hip fracture, smoking, excess alcohol, rheumatoid arthritis, and others) may warrant testing even when OST is favorable. Conversely, a low OST does not replace DXA for diagnosis or for treatment monitoring; it is a screening-oriented signal.
Clinical strengths of OST
- Minimal data requirements: only age and measured weight, which are routinely available.
- Transparent arithmetic: clinicians and patients can verify the score without proprietary tables.
- Fast throughput: suitable for waiting-room screening, outreach clinics, and digital triage when paired with validated weight capture.
- Complements, not replaces, fracture-risk models: OST addresses BMD testing triage; tools such as FRAX incorporate additional risk factors for fracture probability when indicated by local guidance.
Important limitations and caveats
- Population specificity: Performance metrics (sensitivity, specificity, positive predictive value) depend on the underlying prevalence of low BMD and fracture risk in the group studied. Indices derived in one ethnic or geographic population may not transfer perfectly to another without recalibration or updated local evidence.
- Weight accuracy is critical: Home scales, timing relative to meals, edema, and major shifts in body composition can distort the score. For fairness across settings, use a standardized measurement protocol when feasible.
- Not a diagnostic label: OST does not identify vertebral fractures, secondary causes, or treatment thresholds. DXA remains central when BMD measurement is required for diagnosis or therapy decisions.
- Does not encode many major risk factors: Prior fracture, glucocorticoid exposure, and family history are not part of the score; guideline-based indications for testing may still apply when OST is above the cutoff.
- Special populations: Pregnancy, rapid weight change, bariatric surgery, malabsorption, and athletes with very high lean mass may produce misleading relationships between scale weight and bone status relative to the assumptions embedded in the index.
Using this calculator on CalcMD
The CalcMD OST calculator accepts age in years and body weight in kilograms or pounds (pounds are converted automatically). You select sex so the tool applies the appropriate published cutoff (women ≤2, men ≤1). The interface shows the computed OST value, compares it to that cutoff, and lists a stepwise breakdown so the result is auditable in teaching and clinical communication.
Always interpret the output within the patient’s full context: indications for DXA from national or specialty society guidance, eligibility for pharmacologic therapy, fall risk, vitamin D and calcium adequacy, and patient preferences about testing and treatment.
Educational notice: This article and the associated calculator are for education and clinical decision support. They do not establish a doctor–patient relationship, do not replace professional judgment, and are not a substitute for DXA or comprehensive osteoporosis evaluation when indicated.